Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Clinical trial NCT02805660 · TERMINATED
Trial details
- NCT number
- NCT02805660
- Sponsor
- Mirati Therapeutics Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2019-12-14
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.